CL2016001076A1 - (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis. - Google Patents

(aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.

Info

Publication number
CL2016001076A1
CL2016001076A1 CL2016001076A CL2016001076A CL2016001076A1 CL 2016001076 A1 CL2016001076 A1 CL 2016001076A1 CL 2016001076 A CL2016001076 A CL 2016001076A CL 2016001076 A CL2016001076 A CL 2016001076A CL 2016001076 A1 CL2016001076 A1 CL 2016001076A1
Authority
CL
Chile
Prior art keywords
aza
inhibitors
pyridopyrazolopyrimidinones
indazolopyrimidinones
fibrinolosis
Prior art date
Application number
CL2016001076A
Other languages
English (en)
Inventor
Joachim Schuhmacher
Karl-Heinz Schlemmer
Jorma Hassfeld
Tom Kinzel
Johannes Kobberling
Kristin Beyer
Susanne Röhrig
Maria Köllnberger
Michael Sperzel
Nils Burkardt
Matthias Werner
Manuel Ellemann
Grande Yolanda Cancho
Christian Stegmann
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2016001076A1 publication Critical patent/CL2016001076A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPUESTOS DERIVADOS DE (AZA) PIRIDOPIRAZOLOPIRIMIDINONAS E INDAZOLOPIRIMIDINONAS, COMO INHIBIDORES DE FIBRINOLISIS; PROCESO PARA SU PREPARACION; COMPUESTOS INTERMEDIARIOS; MEDICAMENTO QUE LOS COMPRENDE, UTIL PARA EL TRATAMIENTO Y/O PROFILAXIS DE SANGRADO AGUDO Y RECURRENTE EN PACIENTES CON O SIN TRASTORNOS DE SANGRADO HEREDITARIOS O ADQUIRIDOS SUBYACENTES.
CL2016001076A 2013-11-05 2016-05-05 (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis. CL2016001076A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13191642 2013-11-05

Publications (1)

Publication Number Publication Date
CL2016001076A1 true CL2016001076A1 (es) 2016-12-09

Family

ID=49517406

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001076A CL2016001076A1 (es) 2013-11-05 2016-05-05 (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.

Country Status (28)

Country Link
US (3) US9598417B2 (es)
EP (1) EP3066100B1 (es)
JP (1) JP6431061B2 (es)
KR (1) KR102312780B1 (es)
CN (1) CN105683194B (es)
AP (1) AP2016009175A0 (es)
AR (1) AR098292A1 (es)
AU (1) AU2014345771B2 (es)
CA (1) CA2929378C (es)
CL (1) CL2016001076A1 (es)
CR (1) CR20160332A (es)
CU (1) CU24361B1 (es)
DO (1) DOP2016000102A (es)
EA (1) EA029373B1 (es)
ES (1) ES2732305T3 (es)
GT (1) GT201600084A (es)
IL (1) IL244645B (es)
MA (1) MA39018A1 (es)
MX (1) MX370419B (es)
PE (1) PE20160934A1 (es)
PH (1) PH12016500828A1 (es)
SG (1) SG11201602133RA (es)
TN (1) TN2016000161A1 (es)
TW (1) TWI657089B (es)
UA (1) UA117504C2 (es)
UY (1) UY35809A (es)
WO (1) WO2015067549A1 (es)
ZA (1) ZA201602311B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
PE20170920A1 (es) * 2014-11-03 2017-07-12 Bayer Pharma AG Piperidinilpirazolopirimidinonas y utilizacion de las mismas
WO2016173948A1 (en) * 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Indazolopyrimidinones as fibrinolysis inhibitors
WO2017007917A1 (en) * 2015-07-07 2017-01-12 Mast Therapeutics, Inc. Polyoxyethylene/polyoxypropylene copolymers and fibrinolytic inhibitors, uses thereof and compositions
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
CN110590673A (zh) * 2019-09-02 2019-12-20 南通大学 一种4-氯-7-甲基-1h-吲唑及其化学合成方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11654057B2 (en) 2020-04-09 2023-05-23 Bio 54, Llc Devices for bleeding reduction and methods of making and using the same
KR102952279B1 (ko) * 2021-02-05 2026-04-14 시노허브 파마슈티컬 씨오., 엘티디 플라스민 억제제, 이의 제조 방법 및 이의 용도
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CN117500799A (zh) 2021-06-09 2024-02-02 伊莱利利公司 作为kras g12d抑制剂的取代的稠合吖嗪
US11642324B1 (en) 2022-03-01 2023-05-09 Bio 54, Llc Topical tranexamic acid compositions and methods of use thereof
WO2023194222A1 (en) 2022-04-05 2023-10-12 Socpra Sciences Santé Humaines S.E.C. Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2192559A5 (en) * 1972-07-17 1974-02-08 Ugine Kuhlmann Pyrimidino (1,2-b) indazole derivs - inters for dyes and pharmaceuticals, from 3-aminoindazoles and beta-ketone derivs
JP5205053B2 (ja) 2004-07-30 2013-06-05 フェリング ビー．ブイ． トラネキサム酸製剤
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
SI2300462T1 (sl) * 2008-06-06 2014-09-30 Sanofi Makrociklični sečninski in sulfamidni derivati kot inhibitorji za TAFIa
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
KR101675607B1 (ko) 2009-04-07 2016-11-11 에머리티 파마 아베 치료제로서 이소옥사졸-3(2ｈ)-온 유사체
WO2012047156A1 (en) * 2010-10-04 2012-04-12 Astrazeneca Ab Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases
JP2013542243A (ja) * 2010-11-15 2013-11-21 カトリーケ ウニヴェルシテイト ルーヴェン 新規な抗ウイルス性化合物
WO2012082947A1 (en) * 2010-12-16 2012-06-21 Irm Llc Compounds and compositions as tgr5 agonists
US8987286B2 (en) * 2010-12-16 2015-03-24 Bayer Intellectual Property Gmbh Substituted pyrimido[1,2-b]indazoles and their use as modulators of the Pi3K/Akt pathway
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
WO2016173948A1 (en) * 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Indazolopyrimidinones as fibrinolysis inhibitors

Also Published As

Publication number Publication date
ES2732305T3 (es) 2019-11-21
MA39018A1 (fr) 2017-06-30
US10668071B2 (en) 2020-06-02
JP6431061B2 (ja) 2018-11-28
JP2016535052A (ja) 2016-11-10
UY35809A (es) 2015-05-29
MX2016005969A (es) 2016-08-11
EP3066100A1 (en) 2016-09-14
IL244645B (en) 2019-06-30
AR098292A1 (es) 2016-05-26
ZA201602311B (en) 2017-08-30
US20150126449A1 (en) 2015-05-07
NZ718100A (en) 2021-06-25
KR102312780B1 (ko) 2021-10-15
CN105683194B (zh) 2018-09-14
IL244645A0 (en) 2016-04-21
TN2016000161A1 (en) 2017-10-06
US10098883B2 (en) 2018-10-16
US20170239251A1 (en) 2017-08-24
TWI657089B (zh) 2019-04-21
AP2016009175A0 (en) 2016-04-30
CN105683194A (zh) 2016-06-15
UA117504C2 (uk) 2018-08-10
DOP2016000102A (es) 2016-06-30
GT201600084A (es) 2017-07-12
MX370419B (es) 2019-12-11
AU2014345771B2 (en) 2018-09-13
CA2929378A1 (en) 2015-05-14
US20180344739A1 (en) 2018-12-06
CA2929378C (en) 2021-12-07
CU24361B1 (es) 2018-10-04
KR20160079093A (ko) 2016-07-05
HK1223940A1 (zh) 2017-08-11
SG11201602133RA (en) 2016-05-30
PE20160934A1 (es) 2016-10-08
US9598417B2 (en) 2017-03-21
PH12016500828A1 (en) 2016-06-13
CR20160332A (es) 2016-11-10
EA201690935A1 (ru) 2016-10-31
TW201609728A (zh) 2016-03-16
WO2015067549A1 (en) 2015-05-14
AU2014345771A1 (en) 2016-04-14
EP3066100B1 (en) 2019-04-17
EA029373B1 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX378273B (es) Compuestos activos hacia bromodominios.
EA201890204A1 (ru) Антибактериальные соединения
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
EA201990043A1 (ru) Антибактериальные соединения
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX384490B (es) Agentes que inducen apoptosis para el tratamiento de cancer y enfermedades inmunitarias y autoinmunitarias.
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CL2015002692A1 (es) Novedosos compuestos de bencenosulfonamida, método para sintetizarlos y uso de los compuestos en medicina y en cosméticos.
BR112017024163A2 (pt) compostos bicíclicos
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
EA201691773A1 (ru) Галогенированные хиназолин-thf-амины в качестве ингибиторов pde1
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1